Alkermes, Inc.
Inhaled insulin developer reports income of $0.13 per share
Published in Health Business Week, December 9th, 2005
The net income on a GAAP basis for the quarter was $11.8 million or $0.13 per share as compared to a net loss of $14.3 million or $0.16 per share for the quarter ended September 30, 2004.
Alkermes reported a profitable quarter, driven by an increase in total revenues, which included the recognition of net collaborative profit related to work performed on the Vivitrex (naltrexone long-acting injection) program, the receipt of a milestone payment of $9 million from Eli Lilly and Company (Lilly) in conjunction with the initiation of the phase III...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2005-12-09)
More Articles from Health Business Week
- Adams Respiratory Therapeutics, Inc.
Respiratory disorders-focused company posts 81% increase in sales - American Bio Medica Corp.
Immunoassay maker reports 9.7% increase in sales - Aphton Corp.
Immunotherapies developer restructures long-term debt - Becton, Dickinson and Company
Medical diagnostics maker posts 10% increase in revenue - Bio-Rad Laboratories, Inc.
Clinical diagnostics maker posts 9.4% increase in sales - BioVeris Corp.
Vaccine maker reports $0.24 per share loss - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
